Perilous Reversal Stock: Idenix Pharmaceuticals (IDIX)
- IDIX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.4 million.
- IDIX has traded 518,678 shares today.
- IDIX is down 3.1% today.
- IDIX was up 17.1% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in IDIX with the Ticky from Trade-Ideas. See the FREE profile for IDIX NOW at Trade-Ideas More details on IDIX: Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Currently there are 3 analysts that rate Idenix Pharmaceuticals a buy, 2 analysts rate it a sell, and 7 rate it a hold. The average volume for Idenix Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Idenix has a market cap of $1.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.34 and a short float of 24.8% with 11.75 days to cover. Shares are up 34% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Idenix Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 895.0% when compared to the same quarter one year ago, falling from $4.27 million to -$33.96 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, IDENIX PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has significantly decreased to -$29.04 million or 69.05% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- IDENIX PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, IDENIX PHARMACEUTICALS INC continued to lose money by earning -$0.27 versus -$0.56 in the prior year. For the next year, the market is expecting a contraction of 243.7% in earnings (-$0.93 versus -$0.27).
- IDIX, with its very weak revenue results, has greatly underperformed against the industry average of 10.6%. Since the same quarter one year prior, revenues plummeted by 99.9%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- You can view the full Idenix Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.